Aurinia Pharmaceuticals has presented a mixed bag of midphase data on its challenger to Allergan’s blockbuster dry eye drug Restasis. The challenger, VOS, failed to better the tolerability of Restasis but delivered superior efficacy on secondary endpoints, suggesting it may have an unexpected edge over its rival.
